2024 Revenues ($USD) : $28.75B

Gilead Sciences, Inc. posted total revenue of $28.8 billion for 2024, managing a 6% increase compared to the prior year. The main drivers here were better sales coming out of its hiv, oncology, and liver disease franchises. Stripping out Veklury, the company's base business actually looked stronger, growing 8% for the full year and clocking a 13% year-over-year jump in the fourth quarter. Overall Q4 revenue landed at $7.6 billion, also up 6% from Q4 2023.

In its key hiv portfolio, Gilead made some noise at the CROI conference in March 2025, showing off data for an investigational twice-yearly, long-acting treatment candidate. On the regulatory front for hiv prevention, its twice-yearly lenacapavir notched up milestones early in 2025: the EMA accepted its Marketing Authorization Application for review, and the US FDA took its New Drug Applications under Priority Review back in February.

Elsewhere, Gilead picked up a conditional European Marketing Authorization for Seladelpar in February 2025. This one's aimed at primary biliary cholangitis (pbc), which the company is clearly focusing on. Looking broadly, Gilead reported having 54 clinical programs running across virology, oncology, and inflammation. Its R&D muscle seems focused on areas like multiple myeloma, other cancers, and that pbc space within its main therapeutic areas.